Sartorius Stedim Biotech Develops Next Generation of Single-use Bioreactor UniVessel SU
Sartorius Stedim Biotech (SSB), a leading international equipment provider for the biopharmaceutical industry, presents UniVessel SU, the second generation of its successful single-use bioreactor. This single-use stirred tank bioreactor can be operated in a choice of working volumes ranging from 0.6 L to 2 L, and is suitable for the cultivation of mammalian cells, including stem cells, insect and plant cells. Typical areas of application for the UniVessel SU are process development and optimization, as well as production of seed cultures and cell banks.
Fast and flexible for efficient management of peak workloads despite challenging timelines
UniVessel SU combines the proven design of conventional glass vessels with the efficiency and flexibility of single-use systems. Supplied as a completely preassembled and presterilized unit, this laboratory bioreactor is instantly ready to use right out of the box. It eliminates the need for labour-intensive steps, such as autoclaving or installation of probes, minimizing the time needed for preparation. The new UniVessel SU can be used interchangeably with glass vessels to help laboratories better manage peak workloads despite challenging timelines.
Single-use sensors for non-invasive measurement of pH and dissolved oxygen
Each UniVessel SU is equipped with integrated single-use sensors for pH and dissolved oxygen measurement. This proven single-use sensor technology, which SSB also uses in its BIOSTAT RM and BIOSTAT STR disposable bioreactors, measures the pH and DO values non-invasively, thus eliminating time-consuming autoclaving and risk-prone insertion of probes in the culture vessel.
Connection Boxes interface UniVessel SU with existing bioreactor controllers
UniVessel SU is compatible with SSB BIOSTAT controllers and can also be operated with nearly any other brand of bioreactor controller. This saves customers from having to buy expensive new equipment. The new UniVessel SU Connection Box enables the integrated single-use sensors of UniVessel SU to be used with existing controllers. Up to four bioreactor controllers can be interfaced per Connection Box. The sensor calibration data can be read in easily by a barcode scanner in an error-free manner.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...